New RNA cocktail takes on advanced liver cancer in early trial

NCT ID NCT05097911

Ongoing Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tests a new RNA-based drug (MTL-CEBPA) together with two approved immunotherapy drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who have not had prior systemic treatment. The main goals are to find the safest dose and to see how the body handles the combination. Only 33 participants will be enrolled at a single center in Singapore.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MTL-CEBPA (RNA drug) combined with atezolizumab and bevacizumab
What this could lead to: If this combination proves safe and effective, it could offer a new first-line treatment option for advanced liver cancer.
What could go wrong: This is a very early phase 1 trial with only 33 participants, so safety and dosing are the main focus. The drug combination may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

National University Hospital

Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.